Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American Radium Society Appropriate Use Criteria Thoracic Committee.
An expert analysis has concluded that evidence-based guidance from the American Radium Society Appropriate Use Criteria (ARS AUC) Thoracic Committee on several treatment modalities for locally advanced non–small cell lung cancer (LA-NSCLC)—which accounts for 20% to 30% of lung cancer cases at diagnosis—does have utility for optimizing multidisciplinary care in this challenging patient population.
Findings were published online today in JAMA Oncology, with the study investigators noting the need for their review stems from the most recent appropriate use criteria for these patients came out in 2014 and the publication since then of studies examining radiation therapy technique and dosing, and systemic therapy selection. Their systematic literature review involved relevant articles from PubMed—69 references comprising 30 well-designed studies, 9 moderately well-designed studies, 2 studies with design limitations, and 28 nonprimary data references—that were published between January 1966 and December 2022 and focused on combined chemoradiation therapy, dose escalation, consolidation systemic therapy, and palliative radiotherapy.
“Information regarding the treatment of recurrent disease either locally or with oligometastatic disease after primary treatment for LA-NSCLC is increasingly available and should be integrated into modern clinical decision-making,” they wrote. “Additionally, the use of molecular markers such as EGFR, ALK, and PD-L1 has significantly informed systemic therapy options for many patients with NSCLC, and their integration into LA-NSCLC treatment pathways needs to be clarified.”
This consensus-based document encompasses key practice paradigms and 6 typical clinical scenarios in patients with unresectable disease, which covers most patients who have LA-NSCLC, the authors noted:
The ARS AUC Thoracic Committee, citing a lack of uniform guidance, delivers 3 summary recommendations from their review:
“Treatment appropriateness of a variety of LA-NSCLC scenarios was assessed by a consensus-based modified Delphi approach using a range of 3 points to 9 points to denote consensus agreement,” the authors explained regarding how they arrived at their recommendations.
The authors also highlight the importance of multidisciplinary input and shared decision-making with patients who have LA-NSCLC during treatment discussions, concluding that “various surgical, radiotherapeutic, and systemic options are available to manage this challenging patient population.”
Reference
Rodrigues G, Higgins KA, Rimner A, et al. American Radium Society appropriate use criteria for unresectable locally advanced non–small cell lung cancer. JAMA Oncol. Published online April 11, 2024. doi:10.1001/jamaoncol.2024.0294
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen